Ubiquitin signaling in immune responses

Cell Research

Volumn 26, Issue 4, 2016, Pages 457-483

  Hu, Hongbo ^a   Sun, Shao Cong ^b,c  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

adaptive immunity; autoimmunity; immune tolerance; innate immunity; NF B; Peli1; T cell activation; TRAF; ubiquitination

Indexed keywords

CELL SURFACE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; UBIQUITIN;

DENDRITIC CELL; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UBIQUITINATION;

DENDRITIC CELLS; IMMUNE TOLERANCE; IMMUNITY; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UBIQUITIN; UBIQUITINATION;

EID: 84961683180     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2016.40     Document Type: Review

References (278)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-479.
2. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78:399-434.
3. Berndsen CE, Wolberger C. New insights into ubiquitin E3 ligase mechanism. Nat Struct Mol Biol 2014; 21:301-307.
4. Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 2008; 8:501-511.
5. Liu S, Chen ZJ. Expanding role of ubiquitination in NF-κB signaling. Cell Res 2011; 21:6-21.
6. Iwai K. Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol 2012; 22:355-364.
7. Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem 2012; 81:291-322.
8. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54 Pt 1:1-13.
9. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 2015; 33:257-290.
10. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015; 16:343-353.
11. Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol 2012; 4: pii: a006957.
12. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol 2014; 32:461-488.
13. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
14. Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 2009; 227:54-65.
15. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27:229-265.
16. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29:707-735.
17. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13:397-411.
18. Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev 2015; 265:6-21.
19. Caruso R, Warner N, Inohara N, Nunez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 2014; 41:898-908.
20. Dambuza IM, Brown GD. C-type lectins in immunity: recent developments. Curr Opin Immunol 2015; 32:21-27.
21. Dempsey A, Bowie AG. Innate immune recognition of DNA: a recent history. Virology 2015; 479-480:146-152.
22. Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014; 54:289-296.
23. Sun SC, Ley SC. New insights into NF-κB regulation and function. Trends Immunol 2008; 29:469-478.
24. Meylan E, Burns K, Hofmann K, et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-κB activation. Nat Immunol 2004; 5:503-507.
25. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3-and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 2005; 280:36560-36566.
26. Moynagh PN. The roles of Pellino E3 ubiquitin ligases in immunity. Nat Rev Immunol 2014; 14:122-131.
27. Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6:981-988.
28. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-1172.
29. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 2005; 122:669-682.
30. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-β signaling. Mol Cell 2005; 19:727-740.
31. Häcker H, Redecke V, Blagoev B, et al. Specificity in Tolllike receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006; 439:204-207.
32. Oganesyan G, Saha SK, Guo B, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and-independent antiviral response. Nature 2006; 439:208-211.
33. Zeng W, Xu M, Liu S, Sun L, Chen ZJ. Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3. Mol Cell 2009; 36:315-325.
34. Liu S, Chen J, Cai X, et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. eLife 2013; 2:e00785.
35. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455:674-678.
36. Jin L, Waterman PM, Jonscher KR, Short CM, Reisdorph NA, Cambier JC. MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol 2008; 28:5014-5026.
37. Zhong B, Yang Y, Li S, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 2008; 29:538-550.
38. Burdette DL, Monroe KM, Sotelo-Troha K, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011; 478:515-518.
39. Jin L, Hill KK, Filak H, et al. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol 2011; 187:2595-2601.
40. Huang YH, Liu XY, Du XX, Jiang ZF, Su XD. The structural basis for the sensing and binding of cyclic di-GMP by STING. Nat Struct Mol Biol 2012; 19:728-730.
41. Shang G, Zhu D, Li N, et al. Crystal structures of STING protein reveal basis for recognition of cyclic di-GMP. Nat Struct Mol Biol 2012; 19:725-727.
42. Shu C, Yi G, Watts T, Kao CC, Li P. Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol 2012; 19:722-724.
43. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339:786-791.
44. Wu J, Sun L, Chen X, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013; 339:826-830.
45. Zhang X, Shi H, Wu J, et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 2013; 51:226-235.
46. Ablasser A, Hemmerling I, Schmid-Burgk JL, Behrendt R, Roers A, Hornung V. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J Immunol 2014; 192:5993-5997.
47. Gray EE, Treuting PM, Woodward JJ, Stetson DB. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi-Goutieres syndrome. J Immunol 2015; 195:1939-1943.
48. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res 2011; 21:71-85.
49. Sun SC. The noncanonical NF-κB pathway. Immunol Rev 2012; 246:125-140.
50. Jin J, Hu H, Li HS, et al. Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity. Immunity 2014; 40:342-354.
51. Deng L, Wang C, Spencer E, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103:351-361.
52. Wang C, Deng L, Hong M, Akkaraju GR, Inoue JI, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412:346-351.
53. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246:95-106.
54. Tokunaga F. Linear ubiquitination-mediated NF-κB regulation and its related disorders. J Biochem 2013; 154:313-323.
55. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-κB signaling. Cell Res 2011; 21:22-39.
56. Kanayama A, Seth RB, Sun L, et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15:535-548.
57. Kensche T, Tokunaga F, Ikeda F, Goto E, Iwai K, Dikic I. Analysis of nuclear factor-κB (NF-κB) essential modulator (NEMO) binding to linear and lysine-linked ubiquitin chains and its role in the activation of NF-κB. J Biol Chem 2012; 287:23626-23634.
58. Rahighi S, Ikeda F, Kawasaki M, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 2009; 136:1098-1109.
59. Hubeau M, Ngadjeua F, Puel A, et al. New mechanism of X-linked anhidrotic ectodermal dysplasia with immunodeficiency: impairment of ubiquitin binding despite normal folding of NEMO protein. Blood 2011; 118:926-935.
60. Tokunaga F, Sakata S, Saeki Y, et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol 2009; 11:123-132.
61. Iwai K, Fujita H, Sasaki Y. Linear ubiquitin chains: NF-κB signalling, cell death and beyond. Nat Rev Mol Cell Biol 2014; 15:503-508.
62. Shimizu Y, Taraborrelli L, Walczak H. Linear ubiquitination in immunity. Immunol Rev 2015; 266:190-207.
63. Shim JH, Xiao C, Paschal AE, et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19:2668-2681.
64. Thiefes A, Wolter S, Mushinski JF, et al. Simultaneous blockade of NFκB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes. J Biol Chem 2005; 280:27728-27741.
65. Waterfield M, Wei J, Reiley W, Zhang MY, Sun SC. IKKb Is an essential component of the Tpl2 signaling pathway. Mol Cell Biol 2004; 24:6040-6048.
66. Waterfield M, Zhang M, Norman LP, Sun SC. NF-κB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell 2003; 11:685-694.
67. Beinke S, Deka J, Lang V, et al. NF-κB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol 2003; 23:4739-4752.
68. Beinke S, Robinson MJ, Hugunin M, Ley SC. Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105. Mol Cell Biol 2004; 24:9658-9667.
69. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13:679-692.
70. Fukushima T, Matsuzawa S, Kress CL, et al. Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc Natl Acad Sci USA 2007; 104:6371-6376.
71. Yamamoto M, Okamoto T, Takeda K, et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol 2006; 7:962-970.
72. Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKϵ and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4:491-496.
73. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003; 300:1148-1151.
74. McWhirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golen bock DT, Maniatis T. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA 2004; 101:233-238.
75. Hemmi H, Takeuchi O, Sato S, et al. The roles of two IκB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199:1641-1650.
76. Perry AK, Chow EK, Goodnough JB, Yeh WC, Cheng G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 2004; 199:1651-1658.
77. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol 2015; 15:87-103.
78. Wang P, Zhu S, Yang L, et al. Nlrp6 regulates intestinal antiviral innate immunity. Science 2015; 350:826-830.
79. Friedman CS, O'Donnell MA, Legarda-Addison D, et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep 2008; 9:930-936.
80. Zhang M, Wu X, Lee AJ, et al. Regulation of IκB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem 2008; 283:18621-18626.
81. Parvatiyar K, Barber GN, Harhaj EW. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J Biol Chem 2010; 285:14999-15009.
82. Li S, Wang L, Berman M, Kong YY, Dorf ME. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 2011; 35:426-440.
83. Ye JS, Kim N, Lee KJ, Nam YR, Lee U, Joo CH. Lysine 63-linked TANK-binding kinase 1 ubiquitination by mindbomb E3 ubiquitin protein ligase 2 is mediated by the mitochondrial antiviral signaling protein. J Virol 2014; 88:12765-12776.
84. Wang C, Chen T, Zhang J, et al. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. Nat Immunol 2009; 10:744-752.
85. Zhou AY, Shen RR, Kim E, et al. IKKϵ-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/ TRAF2 E3 ubiquitin ligase complex. Cell Rep 2013; 3:724-733.
86. Tseng PH, Matsuzawa A, Zhang W, Mino T, Vignali DA, Karin M. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2010; 11:70-75.
87. Tu D, Zhu Z, Zhou AY, et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 2013; 3:747-758.
88. Wang L, Li S, Dorf ME. NEMO binds ubiquitinated TANK-binding kinase 1 (TBK1) to regulate innate immune responses to RNA viruses. PLoS One 2012; 7:e43756.
89. Zhao T, Yang L, Sun Q, et al. The NEMO adaptor bridges the nuclear factor-κB and interferon regulatory factor signaling pathways. Nat Immunol 2007; 8:592-600.
90. Cui J, Li Y, Zhu L, et al. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat Immunol 2012; 13:387-395.
91. An T, Li S, Pan W, et al. DYRK2 Negatively Regulates Type I Interferon Induction by Promoting TBK1 Degradation via Ser527 Phosphorylation. PLoS Pathog 2015; 11:e1005179.
92. Zhang M, Wang L, Zhao X, et al. TRAF-interacting protein (TRIP) negatively regulates IFN-β production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. J Exp Med 2012; 209:1703-1711.
93. Zheng Q, Hou J, Zhou Y, Yang Y, Xie B, Cao X. Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27. Cell Res 2015; 25:1121-1136.
94. Liu D, Sheng C, Gao S, et al. SOCS3 Drives Proteasomal Degradation of TBK1 and Negatively Regulates Antiviral Innate Immunity. Mol Cell Biol 2015; 35:2400-2413.
95. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7:454-465.
96. Piessevaux J, Lavens D, Peelman F, Tavernier J. The many faces of the SOCS box. Cytokine Growth Factor Rev 2008; 19:371-381.
97. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999; 96:2071-2076.
98. Ori D, Kato H, Sanjo H, et al. Essential roles of K63-linked polyubiquitin-binding proteins TAB2 and TAB3 in B cell activation via MAPKs. J Immunol 2013; 190:4037-4045.
99. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of IκB kinase activation. J Biol Chem 2007; 282:4102-4112.
100. Walsh MC, Kim GK, Maurizio PL, Molnar EE, Choi Y. TRAF6 autoubiquitination-independent activation of the NFκB and MAPK pathways in response to IL-1 and RANKL. PLoS One 2008; 3:e4064.
101. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor-and toll-like receptor-mediated NF-κB activation. Mol Cell Biol 2008; 28:3538-3547.
102. Lee BC, Miyata M, Lim JH, Li JD. Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD88. Proc Natl Acad Sci USA 2016; 113:E165-171.
103. Xia ZP, Sun L, Chen X, et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009; 461:114-119.
104. Gohda J, Matsumura T, Inoue J. Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway in TLR signaling. J Immunol 2004; 173:2913-2917.
105. Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009; 10:1089-1095.
106. Jin W, Chang M, Sun SC. Peli: a family of signal-responsive E3 ubiquitin ligases mediating TLR signaling and T-cell tolerance. Cell Mol Immunol 2012; 9:113-122.
107. Goh ET, Arthur JS, Cheung PC, Akira S, Toth R, Cohen P. Identification of the protein kinases that activate the E3 ubiquitin ligase Pellino 1 in the innate immune system. Biochem J 2012; 441:339-346.
108. Xiao Y, Jin J, Chang M, et al. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat Med 2013; 19:595-602.
109. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011; 11:457-468.
110. Yang XD, Sun SC. Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol Rev 2015; 266:56-71.
111. Jin J, Xiao Y, Hu H, et al. Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages. Nat Commun 2015; 6:5930.
112. Lalani AI, Moore CR, Luo C, et al. Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice. J Immunol 2015; 194:334-348.
113. Lacey DC, Achuthan A, Fleetwood AJ, et al. Defining GMCSF-and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol 2012; 188:5752-5765.
114. Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007; 446:916-920.
115. Gao D, Yang YK, Wang RP, et al. REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-I. PLoS One 2009; 4:e5760.
116. Oshiumi H, Matsumoto M, Hatakeyama S, Seya T. Riplet/ RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-β induction during the early phase of viral infection. J Biol Chem 2009; 284:807-817.
117. Oshiumi H, Miyashita M, Inoue N, Okabe M, Matsumoto M, Seya T. The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe 2010; 8:496-509.
118. Gack MU, Albrecht RA, Urano T, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009; 5:439-449.
119. Rajsbaum R, Albrecht RA, Wang MK, et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog 2012; 8:e1003059.
120. Oshiumi H, Miyashita M, Matsumoto M, Seya T. A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog 2013; 9:e1003533.
121. Lin R, Yang L, Nakhaei P, et al. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Biol Chem 2006; 281:2095-2103.
122. Zhong H, Wang D, Fang L, et al. Ubiquitin-specific proteases 25 negatively regulates virus-induced type I interferon signaling. PLoS One 2013; 8:e80976.
123. Fan Y, Mao R, Yu Y, et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med 2014; 211:313-328.
124. Cui J, Song Y, Li Y, et al. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors. Cell Res 2014; 24:400-416.
125. Pauli EK, Chan YK, Davis ME, et al. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. Sci Signal 2014; 7:ra3.
126. Zhang H, Wang D, Zhong H, et al. Ubiquitin-specific protease 15 negatively regulates virus-induced type I interferon signaling via catalytically-dependent and-independent mechanisms. Sci Rep 2015; 5:11220.
127. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc Natl Acad Sci USA 2007; 104:7500-7505.
128. Inn KS, Gack MU, Tokunaga F, et al. Linear ubiquitin assembly complex negatively regulates RIG-I-and TRIM25-mediated type I interferon induction. Mol Cell 2011; 41:354-365.
129. Inohara N, Koseki T, del Peso L, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB. J Biol Chem 1999; 274:14560-14567.
130. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001; 276:4812-4818.
131. Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004; 14:2217-2227.
132. Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC. Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol 2007; 27:6012-6025.
133. Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem 2007; 282:36223-36229.
134. Hasegawa M, Fujimoto Y, Lucas PC, et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation. EMBO J 2008; 27:373-383.
135. Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009; 30:789-801.
136. Damgaard RB, Nachbur U, Yabal M, et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell 2012; 46:746-758.
137. Krieg A, Correa RG, Garrison JB, et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci USA 2009; 106:14524-14529.
138. Yang S, Wang B, Humphries F, et al. Pellino3 ubiquitinates RIP2 and mediates Nod2-induced signaling and protective effects in colitis. Nat Immunol 2013; 14:927-936.
139. Tao M, Scacheri PC, Marinis JM, Harhaj EW, Matesic LE, Abbott DW. ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways. Curr Biol 2009; 19:1255-1263.
140. Williams KL, Lich JD, Duncan JA, et al. The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor α-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem 2005; 280:39914-39924.
141. Lich JD, Williams KL, Moore CB, et al. Monarch-1 suppresses non-canonical NF-κB activation and p52-dependent chemokine expression in monocytes. J Immunol 2007; 178:1256-1260.
142. Allen IC, Wilson JE, Schneider M, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity 2012; 36:742-754.
143. Zaki MH, Vogel P, Malireddi RK, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011; 20:649-660.
144. Lukens JR, Gurung P, Shaw PJ, et al. The NLRP12 sensor negatively regulates autoinflammatory disease by modulating interleukin-4 production in T cells. Immunity 2015; 42:654-664.
145. Moore CB, Bergstralh DT, Duncan JA, et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008; 451:573-577.
146. Allen IC, Moore CB, Schneider M, et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways. Immunity 2011; 34:854-865.
147. Xia X, Cui J, Wang HY, et al. NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity 2011; 34:843-853.
148. Rebsamen M, Vazquez J, Tardivel A, Guarda G, Curran J, Tschopp J. NLRX1/NOD5 deficiency does not affect MAVS signalling. Cell Death Differ 2011; 18:1387.
149. Soares F, Tattoli I, Wortzman ME, Arnoult D, Philpott DJ, Girardin SE. NLRX1 does not inhibit MAVS-dependent antiviral signalling. Innate immunity 2013; 19:438-448.
150. Benko S, Magalhaes JG, Philpott DJ, Girardin SE. NLRC5 limits the activation of inflammatory pathways. J Immunol 2010; 185:1681-1691.
151. Cui J, Zhu L, Xia X, et al. NLRC5 negatively regulates the NF-κB and type I interferon signaling pathways. Cell 2010; 141:483-496.
152. Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB. Nat Immunol 2012; 13:823-831.
153. Zhang L, Mo J, Swanson KV, et al. NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity 2014; 40:329-341.
154. Kumar H, Pandey S, Zou J, et al. NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections. J Immunol 2011; 186:994-1000.
155. Yao Y, Wang Y, Chen F, et al. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Res 2012; 22:836-847.
156. Meng Q, Cai C, Sun T, et al. Reversible ubiquitination shapes NLRC5 function and modulates NF-κB activation switch. J Cell Biol 2015; 211:1025-1040.
157. Tong Y, Cui J, Li Q, Zou J, Wang HY, Wang RF. Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res 2012; 22:822-835.
158. Tsuchida T, Zou J, Saitoh T, et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 2010; 33:765-776.
159. Zhang J, Hu MM, Wang YY, Shu HB. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J Biol Chem 2012; 287:28646-28655.
160. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci USA 2001; 98:14422-14427.
161. Wang Q, Liu X, Cui Y, et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity 2014; 41:919-933.
162. Zhong B, Zhang L, Lei C, et al. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity 2009; 30:397-407.
163. Qin Y, Zhou MT, Hu MM, et al. RNF26 temporally regulates virus-triggered type I interferon induction by two distinct mechanisms. PLoS Pathog 2014; 10:e1004358.
164. Wang Y, Lian Q, Yang B, et al. TRIM30α is a negative-feedback regulator of the intracellular DNA and DNA virus-triggered response by targeting STING. PLoS Pathog 2015; 11:e1005012.
165. Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol 2013; 14:172-178.
166. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
167. Mayer CT, Berod L, Sparwasser T. Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. Front Immunol 2012; 3:183.
168. Hammer GE, Ma A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013; 31:743-791.
169. Walsh KP, Mills KH. Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol 2013; 34:521-530.
170. Baravalle G, Park H, McSweeney M, et al. Ubiquitination of CD86 is a key mechanism in regulating antigen presentation by dendritic cells. J Immunol 2011; 187:2966-2973.
171. Shin JS, Ebersold M, Pypaert M, Delamarre L, Hartley A, Mellman I. Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature 2006; 444:115-118.
172. van Niel G, Wubbolts R, Ten Broeke T, et al. Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity 2006; 25:885-894.
173. Corcoran K, Jabbour M, Bhagwandin C, Deymier MJ, Theisen DL, Lybarger L. Ubiquitin-mediated regulation of CD86 protein expression by the ubiquitin ligase membrane-associated RING-CH-1 (MARCH1). J Biol Chem 2011; 286:37168-37180.
174. De Gassart A, Camosseto V, Thibodeau J, et al. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc Natl Acad Sci USA 2008; 105:3491-3496.
175. Tze LE, Horikawa K, Domaschenz H, et al. CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J Exp Med 2011; 208:149-165.
176. Ishikawa R, Kajikawa M, Ishido S. Loss of MHC II ubiquitination inhibits the activation and differentiation of CD4 T cells. Int Immunol 2014; 26:283-289.
177. Yang H, Qiu Q, Gao B, Kong S, Lin Z, Fang D. Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation. J Exp Med 2014; 211:2467-2479.
178. Temmerman ST, Ma CA, Borges L, et al. Impaired dendritic-cell function in ectodermal dysplasia with immune deficiency is linked to defective NEMO ubiquitination. Blood 2006; 108:2324-2331.
179. Liu J, Han C, Xie B, et al. Rhbdd3 controls autoimmunity by suppressing the production of IL-6 by dendritic cells via K27-linked ubiquitination of the regulator NEMO. Nat Immunol 2014; 15:612-622.
180. Jin J, Xie X, Xiao Y, et al. Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase Trabid. Nat Immunol 2016; 17:259-268.
181. Hilliard BA, Mason N, Xu L, et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002; 110:843-850.
182. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA 2000; 97:12705-12710.
183. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27:591-619.
184. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol 2010; 28:445-489.
185. Heissmeyer V, Macian F, Im SH, et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 2004; 5:255-265.
186. Huang F, Gu H. Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunol Rev 2008; 224:229-238.
187. Hsu TS, Hsiao HW, Wu PJ, Liu WH, Lai MZ. Deltex1 promotes protein kinase Cθ degradation and sustains Casitas B-lineage lymphoma expression. J Immunol 2014; 193:1672-1680.
188. Park Y, Jin HS, Aki D, Lee J, Liu YC. The ubiquitin system in immune regulation. Adv Immunol 2014; 124:17-66.
189. Balagopalan L, Barr VA, Sommers CL, et al. c-Cbl-mediated regulation of LAT-nucleated signaling complexes. Mol Cell Biol 2007; 27:8622-8636.
190. Balagopalan L, Ashwell BA, Bernot KM, et al. Enhanced T-cell signaling in cells bearing linker for activation of T-cell (LAT) molecules resistant to ubiquitylation. Proc Natl Acad Sci USA 2011; 108:2885-2890.
191. Rodriguez-Pena AB, Gomez-Rodriguez J, Kortum RL, et al. Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules. Gene Ther 2015; 22:781-792.
192. Jeon MS, Atfield A, Venuprasad K, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004; 21:167-177.
193. Huang H, Jeon MS, Liao L, et al. K33-linked polyubiquitination of T cell receptor-ζ regulates proteolysis-independent T cell signaling. Immunity 2010; 33:60-70.
194. Lupher ML Jr, Reedquist KA, Miyake S, Langdon WY, Band H. A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively with ZAP-70 in T cells. J Biol Chem 1996; 271:24063-24068.
195. Rao N, Lupher ML Jr, Ota S, Reedquist KA, Druker BJ, Band H. The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J Immunol 2000; 164:4616-4626.
196. Carpino N, Chen Y, Nassar N, Oh HW. The Sts proteins target tyrosine phosphorylated, ubiquitinated proteins within TCR signaling pathways. Mol Immunol 2009; 46:3224-3231.
197. Carpino N, Turner S, Mekala D, et al. Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. Immunity 2004; 20:37-46.
198. Yang M, Chen T, Li X, et al. K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8+ T cell activation. Nat Immunol 2015; 16:1253-1262.
199. Hu H, Wang H, Xiao Y, et al. Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. J Exp Med 2016; 213:399-414.
200. Evans PC, Taylor ER, Coadwell J, Heyninck K, Beyaert R, Kilshaw PJ. Isolation and characterization of two novel A20-like proteins. Biochem J 2001; 357:617-623.
201. Hu H, Brittain GC, Chang JH, et al. OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. Nature 2013; 494:371-374.
202. Naik E, Webster JD, DeVoss J, Liu J, Suriben R, Dixit VM. Regulation of proximal T cell receptor signaling and tolerance induction by deubiquitinase Usp9X. J Exp Med 2014; 211:1947-1955.
203. Blonska M, Lin X. CARMA1-mediated NF-κB and JNK activation in lymphocytes. Immunol Rev 2009; 228:199-211.
204. Nakaya M, Xiao Y, Zhou X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 2014; 40:692-705.
205. Hamilton KS, Phong B, Corey C, et al. T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Sci Signal 2014; 7:ra55.
206. Shi JH, Sun SC. TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex. Mol Immunol 2015; 68:546-557.
207. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14:289-301.
208. Zhou H, Wertz I, O'Rourke K, et al. Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 2004; 427:167-171.
209. Yamamoto M, Sato S, Saitoh T, et al. Cutting edge: pivotal function of Ubc13 in thymocyte TCR signaling. J Immunol 2006; 177:7520-7524.
210. King CG, Kobayashi T, Cejas PJ, et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Immunol 2006; 12:1088-1092.
211. Stempin CC, Chi L, Giraldo-Vela JP, High AA, Hacker H, Redecke V. The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-κB activation. J Biol Chem 2011; 286:37147-37157.
212. Song R, Kim YW, Koo BK, et al. Mind bomb 1 in the lymphopoietic niches is essential for T and marginal zone B cell development. J Exp Med 2008; 205:2525-2536.
213. Reiley WW, Zhang M, Jin W, et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006; 7:411-417.
214. Reiley WW, Jin W, Lee AJ, et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007; 204:1475-1485.
215. Lee AJ, Zhou X, Chang M, et al. Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J 2010; 29:1600-1612.
216. Tsagaratou A, Trompouki E, Grammenoudi S, Kontoyiannis DL, Mosialos G. Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-κB essential modulator-dependent manner. J Immunol 2010; 185:2032-2043.
217. Zhang J, Stirling B, Temmerman ST, et al. Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 2006; 116:3042-3049.
218. Liu X, Li H, Zhong B, et al. USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. J Exp Med 2013; 210:1575-1590.
219. Coornaert B, Baens M, Heyninck K, et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-κB inhibitor A20. Nat Immunol 2008; 9:263-271.
220. Duwel M, Welteke V, Oeckinghaus A, et al. A20 negatively regulates T cell receptor signaling to NF-κB by cleaving Malt1 ubiquitin chains. J Immunol 2009; 182:7718-7728.
221. Giordano M, Roncagalli R, Bourdely P, et al. The tumor necrosis factor α-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci USA 2014; 111:11115-11120.
222. Park Y, Jin HS, Liu YC. Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex. Proc Natl Acad Sci USA 2013; 110:9433-9438.
223. Chang M, Jin W, Chang JH, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol 2011; 12:1002-1009.
224. Köntgen F, Grumont RJ, Strasser A, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoural immunity, and interleukin-2 expression. Genes Dev 1995; 9:1965-1977.
225. Liou HC, Jin Z, Tumang J, Andjelic S, Smith KA, Liou ML. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int Immunol 1999; 11:361-371.
226. Chen G, Hardy K, Bunting K, Daley S, Ma L, Shannon MF. Regulation of the IL-21 gene by the NF-κB transcription factor c-Rel. J Immunol 2010; 185:2350-2359.
227. Liou HC, Smith KA. The roles of c-rel and interleukin-2 in tolerance: a molecular explanation of self-nonself discrimination. Immunol Cell Biol 2011; 89:27-32.
228. Maggirwar SB, Harhaj EW, Sun SC. Regulation of the interleukin-2 CD28 responsive element by NF-ATp and various NF-kB/Rel transcription factors. Mol Cell Biol 1997; 17:2605-2614.
229. Zhou XY, Yashiro-Ohtani Y, Nakahira M, et al. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol 2002; 168:3847-3854.
230. Ordureau A, Smith H, Windheim M, et al. The IRAK-catalysed activation of the E3 ligase function of Pellino isoforms induces the Lys63-linked polyubiquitination of IRAK1. Biochem J 2008; 409:43-52.
231. Zou Q, Jin J, Hu H, et al. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol 2014; 15:562-570.
232. Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2013; 19:34-41.
233. Zou Q, Jin J, Xiao Y, et al. T cell intrinsic USP15 deficiency promotes excessive IFN-γ production and an immunosuppressive tumor microenvironment in MCA-induced fibrosarcoma. Cell Rep 2015; 13:2470-2479.
234. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435:590-597.
235. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self-shadow within the thymus by the aire protein. Sciece 2002; 298:1395-1401.
236. Abramson J, Goldfarb Y. AIRE: From promiscuous molecular partnerships to promiscuous gene expression. Eur J Immunol 2016; 46:22-33.
237. Kumar PG, Laloraya M, Wang CY, et al. The autoimmune regulator (AIRE) is a DNA-binding protein. J Biol Chem 2001; 276:41357-41364.
238. Uchida D, Hatakeyama S, Matsushima A, et al. AIRE functions as an E3 ubiquitin ligase. J Exp Med 2004; 199:167-172.
239. Bottomley MJ, Stier G, Pennacchini D, et al. NMR structure of the first PHD finger of autoimmune regulator protein (AIRE1). Insights into autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) disease. J Biol Chem 2005; 280:11505-11512.
240. Akiyama T, Maeda S, Yamane S, et al. Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science 2005; 308:248-251.
241. Bonito AJ, Aloman C, Fiel MI, et al. Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest 2013; 123:3510-3524.
242. Zhu M, Fu Y. The complicated role of NF-κB in T-cell selection. Cell Mol Immunol 2010; 7:89-93.
243. Tzachanis D, Lafuente EM, Li L, Boussiotis VA. Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma 2004; 45:1959-1967.
244. Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21:305-334.
245. Mueller DL. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 2004; 5:883-890.
246. Valdor R, Macian F. Induction and stability of the anergic phenotype in T cells. Semin Immunol 2013; 25:313-320.
247. King CG, Buckler JL, Kobayashi T, et al. Cutting edge: requirement for TRAF6 in the induction of T cell anergy. J Immunol 2008; 180:34-38.
248. Heissmeyer V, Vogel KU. Molecular control of Tfh-cell differentiation by Roquin family proteins. Immunol Rev 2013; 253:273-289.
249. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5:853-865.
250. Yu D, Tan AH, Hu X, et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007; 450:299-303.
251. Linterman MA, Rigby RJ, Wong RK, et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009; 206:561-576.
252. Bertossi A, Aichinger M, Sansonetti P, et al. Loss of Roquin induces early death and immune deregulation but not autoimmunity. J Exp Med 2011; 208:1749-1756.
253. Pratama A, Ramiscal RR, Silva DG, et al. Roquin-2 shares functions with its paralog Roquin-1 in the repression of mRNAs controlling T follicular helper cells and systemic inflammation. Immunity 2013; 38:669-680.
254. Vogel KU, Edelmann SL, Jeltsch KM, et al. Roquin paralogs 1 and 2 redundantly repress the Icos and Ox40 costimulator mRNAs and control follicular helper T cell differentiation. Immunity 2013; 38:655-668.
255. Leppek K, Schott J, Reitter S, Poetz F, Hammond MC, Stoecklin G. Roquin promotes constitutive mRNA decay via a conserved class of stem-loop recognition motifs. Cell 2013; 153:869-881.
256. Maruyama T, Araki T, Kawarazaki Y, et al. Roquin-2 promotes ubiquitin-mediated degradation of ASK1 to regulate stress responses. Sci Signal 2014; 7:ra8.
257. Zhang Q, Fan L, Hou F, Dong A, Wang YX, Tong Y. New insights into the RNA-binding and E3 ubiquitin ligase activities of Roquins. Sci Rep 2015; 5:15660.
258. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-787.
259. Proietto AI, van Dommelen S, Zhou P, et al. Dendritic cells in the thymus contribute to T-regulatory cell induction. Proc Natl Acad Sci USA 2008; 105:19869-19874.
260. Oh J, Wu N, Baravalle G, et al. MARCH1-mediated MHCII ubiquitination promotes dendritic cell selection of natural regulatory T cells. J Exp Med 2013; 210:1069-1077.
261. Xie P, Kraus ZJ, Stunz LL, Liu Y, Bishop GA. TNF receptor-associated factor 3 is required for T cell-mediated immunity and TCR/CD28 signaling. J Immunol 2011; 186:143-155.
262. Yi Z, Lin WW, Stunz LL, Bishop GA. The adaptor TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2. Nat Immunol 2014; 15:866-874.
263. Burchill MA, Yang J, Vang KB, et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 2008; 28:112-121.
264. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008; 28:100-111.
265. Yi Z, Stunz LL, Lin WW, Bishop GA. TRAF3 regulates homeostasis of CD8+ central memory T cells. PLoS One 2014; 9:e102120.
266. Chang JH, Hu H, Jin J, et al. TRAF3 regulates the effector function of regulatory T cells and humoral immune responses. J Exp Med 2014; 211:137-151.
267. Harada Y, Harada Y, Elly C, et al. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J Exp Med 2010; 207:1381-1391.
268. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-β sensitivity in vitro and in vivo. J Immunol 2006; 176:1316-1320.
269. Venuprasad K, Huang H, Harada Y, et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol 2008; 9:245-253.
270. Chang JH, Xiao Y, Hu H, et al. Ubc13 maintains the suppressive function of regulatory T cells and prevents their conversion into effector-like T cells. Nat Immunol 2012; 13:481-490.
271. van Loosdregt J, Coffer PJ. Post-translational modification networks regulating FOXP3 function. Trends Immunol 2014; 35:368-378.
272. Chen Z, Barbi J, Bu S, et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 2013; 39:272-285.
273. van Loosdregt J, Fleskens V, Fu J, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 2013; 39:259-271.
274. Zhao Y, Guo H, Qiao G, Zucker M, Langdon WY, Zhang J. E3 ubiquitin ligase Cbl-b regulates thymic-derived CD4+CD25+ regulatory T cell development by targeting Foxp3 for ubiquitination. J Immunol 2015; 194:1639-1645.
275. MacKenzie DA, Schartner J, Lin J, et al. GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 2007; 282:9696-9702.
276. Schartner JM, Singh AM, Dahlberg PE, Nettenstrom L, Seroogy CM. Recurrent superantigen exposure in vivo leads to highly suppressive CD4+CD25+ and CD4+CD25- T cells with anergic and suppressive genetic signatures. Clin Exp Immunol 2009; 155:348-356.
277. Nurieva RI, Zheng S, Jin W, et al. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity 2010; 32:670-680.
278. Lee JH, Elly C, Park Y, Liu YC. E3 Ubiquitin ligase VHL regulates hypoxia-inducible factor-1α to maintain regulatory T cell stability and suppressive capacity. Immunity 2015; 42:1062-1074.